Sampled Announces a $46,000 Spatial Services Grant in Partnership with 10x Genomics
July 13, 2026
Research Opportunity to Use the 10x Genomics Xenium Platform for Spatially Resolved Transcriptomic Profiling and Cell Identity Analysis Piscataway, NJ – Sampled, an integrated analytical laboratory and biorepository, has partnered with 10x Genomics to offer a Spatial In Situ Gene Expression Services Grant, using the Xenium Prime 5K assay, for researchers across the United States. Spatial [...]
July 10, 2026
Proprietary small-molecule formulation extends beyond conventional ROCK inhibitors to accelerate recovery and improve reproducibility in stem cell and organoid research. MONMOUTH JUNCTION, N.J. -- TheWell Bioscience, a leader in xeno-free 3D cell culture technologies, today announced the launch of RocketCell™ Cell Viability Enhancer (1000X), a next-generation cell recovery reagent engineered to maximize cell survival, metabolic [...]
July 10, 2026
Shimadzu Corporation completed the acquisition on July 10 of all shares of Glass HoldCo s.r.o., which indirectly holds all shares of TESCAN GROUP, a.s. (“TESCAN”), a Europe-based pioneer in electron microscopy, thereby making TESCAN a wholly owned subsidiary. This transaction completes the share acquisition procedures for Glass HoldCo s.r.o. that Shimadzu announced on December 25, [...]
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board
July 9, 2026
Dolsten Takes BenchSci's First-Ever Chairman Role as EMET Scales Across Global Biopharma TORONTO — BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. [...]
July 9, 2026
SAN JOSE, Calif. — Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), today announced that Carol Lou will retire as President and Chief Executive Officer of Takara Bio USA on July 10 after more than two decades with the company. Andrew Farmer, D.Phil., who has served as Chief Scientific [...]
AkzoNobel accelerates R&D innovation with Albert Invent
July 9, 2026
Amsterdam, NL / Oakland, CA, USA — AkzoNobel, a global leader in paints and coatings, and Albert Invent, who is building the future of chemistry R&D, today announced an AI transformation partnership with AkzoNobel’s global R&D organization. AkzoNobel’s Digital Workbench initiative is designed to connect laboratory workflows, structure scientific data, and put modern AI tools [...]
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board
July 9, 2026
Dolsten Takes BenchSci's First-Ever Chairman Role as EMET Scales Across Global Biopharma TORONTO -- BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. [...]
July 9, 2026
Uppsala, Sweden – Navinci Diagnostics AB (”Navinci”) today announces that the Company has initiated a pilot project together with Lumito AB (publ) (“Lumito”) to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis. The pilot project aims to combine Lumito’s high-sensitivity image analysis platform with Navinci’s in situ Proximity Ligation Technology (isPLA). By [...]
July 9, 2026
Agreement with leading life sciences company Illumina strengthens Bifrost's path to commercial deployment of next-generation optical pooled screening technology. BERKELEY, Calif. -- Bifrost Biosystems today announced that it has secured a commercial supply agreement with Illumina enabling integration of Illumina's industry-standard sequencing-by-synthesis (SBS) chemistry into its optical pooled screening (OPS) platform slated to be commercially available in early [...]
July 9, 2026
Uppsala, Sweden — Navinci Diagnostics AB (”Navinci”) today announces that the Company has initiated a pilot project together with Lumito AB (publ) (“Lumito”) to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis. The pilot project aims to combine Lumito’s high-sensitivity image analysis platform with Navinci’s in situ Proximity Ligation Technology (isPLA). By [...]

